These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 10803438)

  • 1. The implantable cardioverter-defibrillator.
    Greene HL
    Clin Cardiol; 2000 May; 23(5):315-26. PubMed ID: 10803438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up of patients with unexplained syncope and inducible ventricular tachyarrhythmias: analysis of the AVID registry and an AVID substudy. Antiarrhythmics Versus Implantable Defibrillators.
    Steinberg JS; Beckman K; Greene HL; Marinchak R; Klein RC; Greer SG; Ehlert F; Foster P; Menchavez E; Raitt M; Wathen MS; Morris M; Hallstrom A
    J Cardiovasc Electrophysiol; 2001 Sep; 12(9):996-1001. PubMed ID: 11573709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators.
    Domanski MJ; Sakseena S; Epstein AE; Hallstrom AP; Brodsky MA; Kim S; Lancaster S; Schron E
    J Am Coll Cardiol; 1999 Oct; 34(4):1090-5. PubMed ID: 10520795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(14):1-74. PubMed ID: 23074465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
    Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
    N Engl J Med; 1997 Nov; 337(22):1576-83. PubMed ID: 9411221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The implantable cardioverter defibrillator and primary prevention of sudden death: the Multicenter Automatic Defibrillator Implantation Trial and the Coronary Artery Bypass Graft (CABG)-Patch Trial.
    Block M; Breithardt G
    Am J Cardiol; 1999 Mar; 83(5B):74D-78D. PubMed ID: 10089844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design.
    Raviele A; Bongiorni MG; Brignole M; Cappato R; Capucci A; Gaita F; Mangiameli S; Montenero A; Pedretti R; Salerno J; Sermasi S
    Am J Cardiol; 1999 Mar; 83(5B):104D-111D. PubMed ID: 10089851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of EP-guided therapy in ventricular arrhythmias: beta-blockers, sotalol, and ICD's.
    Capucci A; Aschieri D; Villani GQ
    J Interv Card Electrophysiol; 2000 Jan; 4 Suppl 1():57-63. PubMed ID: 10590490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants.
    Fromer M; Brachmann J; Block M; Siebels J; Hoffmann E; Almendral J; Ohm OJ; den Dulk K; Coumel P; Camm AJ
    Circulation; 1992 Aug; 86(2):363-74. PubMed ID: 1638705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.
    Raitt MH; Klein RC; Wyse DG; Wilkoff BL; Beckman K; Epstein AE; Coromilas J; Friedman PL; Martins J; Ledingham RB; Greene HL;
    Am J Cardiol; 2003 Apr; 91(7):812-6. PubMed ID: 12667566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%.
    Grimm W; Hoffmann J Jü; Müller HH; Maisch B
    J Am Coll Cardiol; 2002 Mar; 39(5):780-7. PubMed ID: 11869841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study.
    Cappato R
    Am J Cardiol; 1999 Mar; 83(5B):68D-73D. PubMed ID: 10089843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of event rates and survival in patients with unexplained syncope without documented ventricular tachyarrhythmias versus patients with documented sustained ventricular tachyarrhythmias both treated with implantable cardioverter-defibrillators.
    Pires LA; May LM; Ravi S; Parry JT; Lal VR; Nino CL
    Am J Cardiol; 2000 Mar; 85(6):725-8. PubMed ID: 12000047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ventricular tachyarrhythmia recurrence in primary versus secondary implantable cardioverter-defibrillator patients and role of electrophysiology study.
    Zaman S; Sivagangabalan G; Chik W; Stafford W; Hayes J; Denman R; Young G; Sanders P; Kovoor P
    J Interv Card Electrophysiol; 2014 Dec; 41(3):195-202. PubMed ID: 25267274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of nonsustained ventricular tachycardia after revascularization.
    Mittal S; Lomnitz DJ; Mirchandani S; Stein KM; Markowitz SM; Slotwiner DJ; Iwai S; Das MK; Lerman BB
    J Cardiovasc Electrophysiol; 2002 Apr; 13(4):342-6. PubMed ID: 12033350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score.
    Younis A; Goldberger JJ; Kutyifa V; Zareba W; Polonsky B; Klein H; Aktas MK; Huang D; Daubert J; Estes M; Cannom D; McNitt S; Stein K; Goldenberg I
    Eur Heart J; 2021 May; 42(17):1676-1684. PubMed ID: 33417692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic decision tree for patients with sustained ventricular tachyarrhythmias or aborted cardiac arrest: a critical review of the Antiarrhythmics Versus Implantable Defibrillator trial and the Canadian Implantable Defibrillator Study.
    Farré J; Cabrera JA; Romero J; Rubio JM
    Am J Cardiol; 2000 Nov; 86(9A):44K-51K. PubMed ID: 11084100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.